Proactive Investors - Run By Investors For Investors

CytoDyn presents 'stunning' data on treatment of HIV at Seattle conference

CytoDyn Inc (OTCQB:CYDY) CEO Dr. Nader Pourhassen and Dr. Richard Pestell tell Proactive Investors that Pourhassen presented data on its anti-HIV therapy at the Conference on Retroviruses and Opportunistic Infections in Seattle this week.

Highlights of the data include that patients had passed 12 weeks with close to 90% responders rate after the first induction period. And the company is ready to submit a pivotal trial to the FDA this month for final approval as a label expansion for mono-therapy.

 
View full CYDY profile View Profile

CytoDyn Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use